{
    "clinical_study": {
        "@rank": "114250", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "240 mg neratinib"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Experimental", 
                "description": "240 mg neratinib plus 8 mg temsirolimus with optional dose escalation to 15 mg temsirolimus"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 2, therapeutic-exploratory, adaptive design, open-label, multicenter,\n      multinational study evaluating neratinib monotherapy and neratinib plus temsirolimus\n      combination therapy in patients with non-small cell lung cancer (NSCLC) who have documented\n      somatic HER2 mutations and who have received at least one prior cytotoxic chemotherapy\n      regimen."
        }, 
        "brief_title": "Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "HER2-mutant Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 2, therapeutic-exploratory, adaptive design, open-label, multicenter,\n      multinational study evaluating neratinib monotherapy and neratinib plus temsirolimus\n      combination therapy in patients with NSCLC who have documented somatic HER2 mutations and\n      who have received at least one prior cytotoxic chemotherapy regimen. Patients will be\n      randomized at study entry into 1 of 2 treatment arms:\n\n        -  Arm A: neratinib 240 mg orally once daily,\n\n        -  Arm B: neratinib 240 mg orally once daily plus temsirolimus 8 mg once weekly by\n           intravenous (IV) infusion.\n\n      In the case of disease progression, patients initially assigned to the neratinib monotherapy\n      arm will be given the option to add temsirolimus 8 mg IV once weekly.\n\n      All patients on combination therapy may be dose-escalated with respect to temsirolimus dose\n      to 15 mg/week at the end of first cycle of treatment with the combination, if well tolerated\n      and at the physician's discretion. In the event that the neratinib 240 mg/day plus\n      temsirolimus 15 mg/week dose is not well tolerated, the patient will be subsequently dose\n      reduced back to neratinib 240 mg/day plus temsirolimus 8 mg/week.\n\n      Dosing will be continuous on nominal 3-week cycles until evidence of progressive disease,\n      unacceptable toxicity, or patient withdrawal of consent.\n\n      All eligible patients enrolled will have their disease measured radiographically at\n      baseline. Patients will undergo radiographic evaluation of their disease every 6 weeks until\n      disease progression or withdrawal from the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged \u226518 years at the time of signing the informed consent.\n\n          -  Histologically confirmed diagnosis of NSCLC, advanced (stage IIIB) or metastatic\n             (stage IV).\n\n          -  Documented somatic ErbB2 (HER2) activating mutation.\n\n        Exclusion Criteria:\n\n          -  Previous treatment with any investigational agent \u226430 days prior to the initiation of\n             investigational products.\n\n          -  Prior exposure to tyrosine kinase inhibitor including neratinib, lapatinib, and\n             afatinib (excluding dacomitinib), or mTOR inhibitor.\n\n        Note: There are additional inclusion and exclusion criteria.  The study center will\n        determine if you meet all of the criteria."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "104", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01827267", 
            "org_study_id": "PUMA-NER-4201", 
            "secondary_id": "2012-004743-68"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "A", 
                    "B"
                ], 
                "description": "240 mg orally, once daily with food, continuously in 21 day cycles", 
                "intervention_name": "neratinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B", 
                "description": "8 mg or 15 mg weekly by IV infusion", 
                "intervention_name": "temsirolimus", 
                "intervention_type": "Drug", 
                "other_name": "Torisel"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Lung cancer", 
            "Puma", 
            "neratinib"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94040"
                    }, 
                    "name": "UCLA"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado"
                    }, 
                    "name": "University of Colorado"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Moffit"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21231"
                    }, 
                    "name": "Johns Hopkins"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Dana Farber"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Massachusettes General Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "Washington University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Ohio State University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15232"
                    }, 
                    "name": "University of Pittsburgh Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "UT Southwestern"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MD Anderson"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grenoble", 
                        "country": "France", 
                        "zip": "38043"
                    }, 
                    "name": "CHU de Grenoble Hopital Albert Michallon"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "CHRU de Lille - Hopital Calmette"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13915"
                    }, 
                    "name": "Hopital Nord"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France", 
                        "zip": "167091"
                    }, 
                    "name": "Hopitaux universitaires de Strasbourg Nouvel Hopital Civil"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "30030"
                    }, 
                    "name": "CHU de Toulous Hopital Larre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94805"
                    }, 
                    "name": "Institut Gustave Roussy"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients With Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations", 
        "overall_contact": {
            "email": "clinicaltrials@pumabiotechnology.com", 
            "last_name": "Puma Biotechnology Clinical Operations", 
            "phone": "+1-424-248-6500"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "ORR is defined as Complete Response (CR) and Partial Response (PR) after receiving at least one prior regimen of chemotherapy", 
            "measure": "Overall Response Rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "minimum 21 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01827267"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "CBR is defined as the percentage of patients with CR plus PR plus Stable Disease (SD)", 
                "measure": "Clinical Benefit Rate (CBR)", 
                "safety_issue": "No", 
                "time_frame": "at least 12 weeks"
            }, 
            {
                "description": "DOR is defined as the date when criterion of CR or PR is first met and subsequently confirmed (whichever status is recorded first) to the first date of documented disease progression", 
                "measure": "Duration of Response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "Estimated 6 months"
            }, 
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Estimated 6 months"
            }, 
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Estimated 12 months"
            }, 
            {
                "measure": "Safety (Adverse Events [AEs] and Serious Adverse Events [SAEs])", 
                "safety_issue": "Yes", 
                "time_frame": "Estimated 6 months"
            }, 
            {
                "description": "Validated Quality of Life Questionnaires", 
                "measure": "Change from baseline in quality of life measured using EQ-5D-5L and FACT-L", 
                "safety_issue": "No", 
                "time_frame": "Estimated 6 months"
            }
        ], 
        "source": "Puma Biotechnology, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Puma Biotechnology, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}